Studies have shown that CDK1 is active in the cell cycle of several tumor-regulating cell adhesion [20] and can be used as clinical prognostic biomarkers for nonsmall cell lung cancer [21], colon cancer [22], breast cancer [23], and ovarian cancer [24]. This evidence concerns the gene CDK1 and breast cancer.